Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Mundipharma receives CHMP positive opinion for Nyxoid® (intranasal naloxone spray)

Posted on: 17 Sep 17

·         Nyxoid® (intranasal naloxone spray) set to be the first pan-EU intranasal formulation available for the reversal of opioid overdose

·         Novel formulation designed to support take-home naloxone programmes and provide ‘first responders’ with a needle-free option


Cambridge, UK, 15 September 2017 – Mundipharma today announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Nyxoid® (intranasal naloxone 1.8 mg)[i] for use in the emergency reversal of opioid overdose. If approved, this will be the first intranasal formulation of naloxone to receive a pan-EU approval. The European Commission will now review the CHMP opinion and a final decision is expected in Q4 2017.


Opioid-induced death represents a significant public health problem responsible for 82 per cent of fatal drug overdoses in the EU, the majority of which are associated with heroin.[ii] Naloxone has been used in routine practice to reverse the effects of opioid overdose for more than 40 years, and is included in the World Health Organization (WHO) Model List of Essential Medicines.[iii] Mundipharma has developed an intranasal formulation to provide potential ‘first responders’ in overdose situations with an easy to use, needle-free option that is suitable for use in a take-home naloxone setting.


Rachel Gooch, Head of Addiction Therapy, at Mundipharma International Limited, said: “This positive opinion is a significant step for Mundipharma and we look forward to the final European Commission decision in Q4 2017. For many years naloxone has been a cornerstone of the emergency reversal of opioid overdose, however it must be delivered rapidly in order to preserve life.  We know that a longer period between overdose and the arrival of emergency services can lead to a greater risk of severe damage or death. [iv] We therefore expect the availability of an easy to use, needle-free option, suitable for use in take home setting, to be a welcome additional treatment option with potential to reduce the overall number of opioid-related overdose deaths in Europe.”


Mundipharma’s submission for approval for Nyxoid is based on data from a 5 part, single site, open label, randomised, single dose, crossover study involving 38 healthy volunteers. It is anticipated that Nyxoid (1.8 mg naloxone) will deliver therapeutic concentrations comparable with an IM dose of 0.4 mg, currently regarded as the standard of care in the event of opioid overdose.[v] The product is well tolerated with a similar side-effect profile to that of injectable naloxone.[vi]


* Nyxoid contains 1.8 mg naloxone, which is equivalent to 2 mg naloxone hydrochloride.

Editor's Details

Mike Wood

Last updated on: 17/09/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.